After a median follow-up of 9.9 months, 38% of the trial participants experienced some degree of tumor shrinkage after receiving Opdivo in combination with Yervoy. Combining Opdivo (nivolumab) and ...
As September concludes, the landscape of GU oncology continues to evolve, with important developments in prostate, bladder, ...
Reasons for pursuing genomic profiling among patients with metastatic genitourinary cancers included guiding treatment and improving therapeutic response, in which age and education level were found ...
Blunt injury to the bladder is associated with a mortality rate of 22%, and therefore appropriate evaluation of the injury is crucial. The question of which patients should receive genitourinary ...
Conferring with a patient about treatment. The VES-13, a brief frailty screening tool, was found effective in determining which older patients with GU cancer were at higher risk for adverse outcomes ...
Stage at presentation and survival outcomes of patients with Gleason 8 to 10 prostate cancer and low PSA. Association of baseline perineural invasion with shorter time to progression in men with ...
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic. Preliminary survey findings presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback